Investigational drug · Phase 2
AGA2115
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Osteogenesis Imperfecta (OI).
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "AGA2115"
First trial start
2025
Dec 12, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AGA2115", any sponsor or status.
Conditions studied
As listed on its trial records.
- Osteogenesis Imperfecta (OI)
Largest trials
Live from ClinicalTrials.gov: studies naming "AGA2115" as an intervention, largest first.
Angitia Incorporated LimitedIndustry
NCT07062588 · 80 participants (planned) · Start Dec 12, 2025 · Primary completion Nov 2027
Drug: AGA2115 · For: Osteogenesis Imperfecta (OI)
Sites: Phoenix, Arizona; New Haven, Connecticut; Wilmington, Delaware · 26 sites in all
Angitia Incorporated LimitedIndustry
NCT06086613 · 72 participants · Start Oct 3, 2023 · Primary completion Oct 17, 2024
Drug: AGA2115; Placebo · For: Osteogenesis Imperfecta
Sites: Lake Forest, California
- A Dose REgimen-Finding Study of AGA2115 in Chinese Patients With Osteogenesis ImpeRfecta (EIR)Recruiting
Angitia Biopharmaceuticals Guangzhou LimitedIndustry
NCT07557446 · 48 participants (planned) · Start Jul 14, 2026 · Primary completion Apr 2028
Drug: AGA2115 · For: Osteogenesis Imperfecta (OI)
Sites: Beijing, China; Shenzhen, China; Changsha, China · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.